Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

5.6K
Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.6K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism01:21

Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism

241
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
241

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comment on "Avian-inspired Analogies in Dermatology".

Indian dermatology online journal·2026
Same author

Elegy on the death of a pemphigus patient.

Indian journal of dermatology, venereology and leprology·2026
Same author

Pre- and Post-Exposure Prophylaxis in Sexually Transmitted Diseases: An Uncharted Territory.

Indian journal of dermatology·2024
Same author

A Critical Appraisal of Gluten in Skin Disorders, the Evidence So Far, and Updated Recommendations.

Indian journal of dermatology·2024
Same author

Biases in dermatology: A primer.

Indian journal of dermatology, venereology and leprology·2024
Same author

Bathing Practices in Dermatology: Uses and Implications for Patient Management.

Indian dermatology online journal·2023

Related Experiment Video

Updated: May 9, 2025

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
15:23

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease

Published on: May 13, 2010

19.3K

Abametapir: A New Solution to an Age Old Problem.

Atreyo Chakraborty1

  • 1Department of Dermatology Venereology and Leprosy, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.

International Journal of Trichology
|May 1, 2025
PubMed
Summary
This summary is machine-generated.

Abametapir, a novel metalloproteinase inhibitor approved in July 2020, offers a unique dual-action topical treatment for lice by targeting both adult parasites and their eggs. This new pediculocide provides a potential advancement in treating head lice infestations.

Keywords:
Abametapirhead licelicepediculocidepediculosis capitis

More Related Videos

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
06:44

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Published on: January 10, 2025

383
Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
08:48

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

11.7K

Related Experiment Videos

Last Updated: May 9, 2025

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
15:23

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease

Published on: May 13, 2010

19.3K
Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
06:44

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Published on: January 10, 2025

383
Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
08:48

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

11.7K

Area of Science:

  • Pharmacology
  • Dermatology
  • Parasitology

Background:

  • Head lice infestations (pediculosis) are a common public health concern.
  • Existing treatments often face challenges with resistance and efficacy against louse eggs.
  • Metalloproteinases play a crucial role in the hatching process of louse eggs.

Purpose of the Study:

  • To introduce Abametapir, a newly approved topical pediculocide.
  • To discuss the novel mechanism of action of Abametapir.
  • To review the development, usage, and adverse effects of Abametapir.

Main Methods:

  • Review of Abametapir's development history.
  • Analysis of its mechanism of action as a metalloproteinase inhibitor.
  • Summary of clinical data regarding its efficacy and safety.

Main Results:

  • Abametapir received FDA approval in July 2020 for topical use.
  • It uniquely targets metalloproteinases essential for both egg hatching and adult louse survival.
  • The drug presents a new therapeutic option for managing pediculosis.

Conclusions:

  • Abametapir represents a significant advancement in topical pediculicides.
  • Its dual-action mechanism offers a novel approach to combating lice and preventing re-infestation.
  • Dermatologists should be aware of this new treatment option for their patients.